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Background. The prevailing hypothesis regards schizophrenia as a polygenic disease, in which multiple genes combine with
each other and with environmental stimuli to produce the variance of its clinical symptoms. We investigated whether the
ubiquitous transcription factor Sp1 is abnormally expressed in schizophrenia, and consequently can affect the expression of
genes implicated in this disorder. Methodology/Principal Findings. mRNA of Sp1 and of mitochondrial complex I subunits
(NDUFV1, NDUFV2) was analyzed in three postmortem brain regions obtained from the Stanley Foundation Brain Collection,
and in lymphocytes of schizophrenic patients and controls. Sp1 role in the transcription of these genes was studied as well. Sp1
was abnormally expressed in schizophrenia in both brain and periphery. Its mRNA alteration pattern paralleled that of NDUFV1
and NDUFV2, decreasing in the prefrontal cortex and the striatum, while increasing in the parieto-occipital cortex and in
lymphocytes of schizophrenic patients as compared with controls. Moreover, a high and significant correlation between these
genes existed in normal subjects, but was distorted in patients. Sp1 role in the regulation of complex I subunits, was
demonstrated by the ability of the Sp1/DNA binding inhibitor, mithramycin, to inhibit the transcription of NDUFV1 and
NDUFV2, in neuroblastoma cells. In addition, Sp1 activated NDUFV2 promoter by binding to its three GC-boxes. Both activation
and binding were inhibited by mithramycin. Conclusions/Significance. These findings suggest that abnormality in Sp1,
which can be the main activator/repressor or act in combination with additional transcription factors and is subjected to
environmental stimuli, can contribute to the polygenic and clinically heterogeneous nature of schizophrenia.
Citation: Ben-Shachar D, Karry R (2007) Sp1 Expression Is Disrupted in Schizophrenia; A Possible Mechanism for the Abnormal Expression of
Mitochondrial Complex I Genes, NDUFV1 and NDUFV2. PLoS ONE 2(9): e817. doi:10.1371/journal.pone.0000817
INTRODUCTION
Schizophrenia is known for its great heterogeneity across
individuals and variation in symptoms within individuals over
time [1,2]. Based on family, twin, and adoption studies, it is
accepted that genes play a major role in the susceptibility for
schizophrenia. Like most other complex disorders, schizophrenia
is currently believed to be a polygenic disease. Molecular studies in
schizophrenia, mostly in post mortem brains, have unraveled
abnormalities in a variety of functional groups of genes. For
example, reduced expression was observed in genes associated
with synaptic architecture and transmission including the pre-
synaptic vesicle proteins such as the synapsins [3], the SNARE
vesicle-docking complex and synaptosomal-associated protein-25
(SNAP-25) [4,5]. In addition, reduced expression of synaptic
proteins such as neuregulin 1 [6], dysbindin, regulator of G-
protein signaling 4 (RGS4) [6,7], and of reelin, which is secreted
by GABAergic neurons in association with dendritic specializa-
tions [8], were reported. Abnormalities were also observed in
genes associated with metabolism and/or receptors of schizophre-
nia-relevant neurotransmitters including dopamine (DA) (DA D3/
D4 receptors, COMT) GABA (GAD67, GABA(A) receptor) and
glutamate (GLUR1/2, NMDA NR1/2, PSD proteins) [9,10].
Recently, a robust change was demonstrated in genes and proteins
associated with mitochondria in schizophrenia, including those
encoding the oxidative phosphorylation systems (OXPHOS) [11–
13]. It is therefore currently hypothesized that in complex
disorders such as schizophrenia, susceptible genes can combine
with each other and with environmental modifiers as well as with
other modulating unaffected genes to produce the variance in the
syndromal picture of the disorder.
We further hypothesize that an abnormality in a ubiquitous
transcription factor that participates in the regulation of
numerous genes, either as the main activator/repressor or in
combination with additional transcription factors, all differentially
subjected to environmental stimuli, can lead to the heterogeneity
observed in schizophrenia. The transcription factor Specificity
protein 1 (Sp1), is such a candidate. Sp1 is the prototype of
a family of zinc finger (Cys2/Hys2) DNA binding transcription
factors that binds to and acts through G-rich elements such as
GC-box. It is generally accepted that this extremely versatile
protein is involved in the expression of many different genes and
can be regulated at the level of transcription and post-trans-
lational modifications such as phosphorylation and/or glycosyl-
ation [14]. Among the various factors that can modulate Sp1
activity are glucose, insulin and several kinases including CDK2
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well as heterotypic interactions with different classes of transcrip-
tion factors including the TATA-box binding protein (TBP),
TPB-associated factors (TAFs) and Sp3 [14,18]. Interestingly, Sp1
is involved in the regulation of several genes which have been
implicated in schizophrenia such as reelin, GAD67, MAOA/B,
NMDA receptor subunits NR1 and NR2A/B, GABA A and DA
receptors D1A and D2/3 [19–24]. In addition, Sp1 is involved in
the regulation and coordination of nuclear encoded mitochon-
drial genes including some which encode for OXPHOS proteins
[25,26]. In line with the latter, it is noteworthy that GC-box
binding sites for Sp1 are found in most, if not all, OXPHOS
promoters characterized to date, and in several of them are the
only putative binding sites [25].
Accumulating data points to abnormalities in the OXPHOS
enzyme activity as well as mRNA and protein expression in
schizophrenia both in periphery and in brain [11,12,27–32]. We
have previously reported disease specific and state dependent
alterations in complex I activity, which was shown to play a major
role in controlling oxidative phosphorylation in synaptic mito-
chondria [33], in lymphocytes, and platelets of schizophrenic
patients. These changes were associated with region specific
alterations in postmortem brain and in periphery, of mRNA and
protein expression of three complex I subunits, the 24kDa
(NDUFV2), the 51kDa (NDUFV1) and the 75kDa (NDUFS1)
subunit, all forming one functional subunit [34].
Herein we show for the first time that in schizophrenia Sp1
mRNA levels are altered in three different brain areas and in the
periphery in a region specific manner. Moreover, Sp1 changes
parallel the tissue specific pattern of change in the expression of
NDUFV1 and NDUFV2 in all four tissues. In addition, a high and
significant correlation between these genes is observed in normal
subjects but is distorted in patients. We further show that the
inhibition of Sp1 binding to DNA, by mithramycin, modulates the
expression of NDUFV2, NDUFV1, NDUFS1 and RELN (reelin), all
reported to be altered in brains of schizophrenic patient.
Moreover, the TATA-less 59-flanking sequence of the human
NDUFV2, which was the most affected subunit of complex I in
schizophrenia, demonstrated a promoter activity. This promoter
sequence contains three regulatory elements that were recognized
by Sp1. These results suggest Sp1 as a pathological factor in
schizophrenia, which may explain the multi-gene manifestation of
this disorder.
MATERIALS AND METHODS
Subjects
Ten inpatients who met DSM-IV criteria for schizophrenia and
had pronounced positive symptoms (PANSS scores $ 20)
participated in the study. Consensus diagnosis by two senior
psychiatrists was based on extended clinical interview and patients’
chart review. Severity of symptoms was evaluated using the
Positive and Negative Symptom Scale (PANSS) for schizophrenia
and the Clinical Global Impression (CGI) scale. All patients were
treated with antipsychotic medications. Patients with schizoaffec-
tive illness were excluded. Ten age and sex matched subjects
without prior psychiatric history served as controls. Excluded from
the study were subjects suffering from a severe current medical
condition, present or past neurological disorder, history of head
trauma with loss of consciousness greater than 10 minutes or any
medical condition requiring somatic medication. All subjects were
given an explanation on the purpose of the study and provided
a written informed consent. The study was approved by The
Rambam Medical Center Institutional Review Board.
Isolation of platelets and lymphocytes
Blood (20 ml) was collected from the cubital vein without
tourniquet between 8.00 and 10.00AM. Platelets were isolated
from platelet-rich plasma (1–2 hr after blood sampling) by
centrifugation at 10006g for 30 min. Lymphocytes were separated
on Ficoll-Plaque gradients by centrifugation at 4006g for 30 min.
Platelets or lymphocytes were immediately further processed and
total RNA was isolated
Post-mortem tissues
Frozen samples from the prefrontal cortex, including the middle
frontal gyrus of the frontal lobe (BA46/9), from the ventral
parieto-occipital cortex (BA19) and from the striatum including
a part of the nucleus accumbance, were provided by the Stanley
Foundation Neuropathology Consortium (Bethesda, MD). Sam-
ples were obtained from individuals diagnosed with schizophrenia
(DSM-IV criteria, n=15) and from normal controls (n=15). The
groups were matched by age, sex, race, postmortem interval
(PMI), pH, side of brain, and mRNA quality. Demographic data
are presented in Table 1. A description of the Stanley Brain
Collection and more detailed demographics and samples’ quality
were previously reported [35]. All samples were analyzed in
parallel, blind to patients’ diagnosis. Protection of human rights
and detailed information regarding the selection of specimen can
be found in [35]. In short, for all specimens a pathologist contacted
the family of the deceased to make a preliminary diagnosis and
requested permission for donation of the brain and for the release
of the deceased’s medical records. No name or other identifying
information was given for the deceased.
Cell culture
SH-SY5Y or SK-N-SH human neuroblastoma cells were grown at
37uC, with 5% CO2 in Dulbecco’s modified Eagle’s Medium
(DMEM) containing 4.5 gm/l D-Glucose and supplemented with
2 mM L-glutamine, 100 U/ml streptomycin/penicillin and 10%
FCS. To inhibit Sp1-DNA binding, cells were grown in the
presence of 100–400 nM mithramycin in serum free medium for
12–48 hrs. Cell viability was determined by Trypan Blue.
Mithramycin at concentration,200 nM for up to 36 hrs had no
effect on cell viability. The following experiments were performed
in the presence of 150 nM mithramycin for 24 hrs.
RNA extraction
RNA extraction from blood cells or tissue was performed using
RNA STAT-60 kit (TEL-TEST, INC, Frienwood, TX, USA). For
further purification of RNA, the phenol:chloroform:isoamyl
alcohol (25:24:1) step was performed twice. All RNA preparations
were dissolved in RNase free water and were then treated by
DNase as previously described [29]. The final RNA preparation
was dissolved in RNase free water and stored in 280uC until use.
RNA integrity, depicted in the form of three bands corresponding
to 28S, 18S and 5S RNA, was assessed by electrophoresis in a 1%
agarose/formaldehyde gel stained with ethidium bromide. The
amount of RNA extracted was determined spectophotometricaly
at 260 nm.
RT-PCR analysis
The expression of the different genes was studied by using RT-
PCR[29]. 5 mg of total RNA were reverse transcribed using
Moloney Murine Leukemia Virus (M-MLV) reverse transcriptase
(Promega, Madison, WI, USA). Amplification of RT-cDNA was
initially performed on a control specimen at different concentra-
Schizophrenia, Sp1 & Complex I
PLoS ONE | www.plosone.org 2 September 2007 | Issue 9 | e817tions to define a linear range for all genes. The number of cycles,
cDNA amount and primers concentration was established
according to a stringent calibration process determining the log-
linear phase of amplification for each gene. After establishing the
optimal reaction conditions, PCR amplification was performed at
least twice per individual. PCR products were stained with
ethidium bromide and analyzed by electrophoresis on 2% agarose
gel. Results were analyzed by densitometer. Sequences of PCR
primers for NDUFV2, NDUFV1 NDUFS1, RELN , Sp1, 18S-RNA
and b-actin were designed according to sequence obtained from
Gene-Bank (Table 2). b-actin and 18S-RNA were used for
assessment of RNA quality and yield. The b-actin was used for
normalizing variations in RNA aliquots taken for RT reactions. A
single batch of RNA isolated from human platelets, on which PCR
was performed at three different concentrations, was assayed in
parallel with each set of samples and served as a positive control
and to ensure linearity. All subject samples were further
normalized to this positive control to enable comparison between
samples.
Promoter luciferase constructs
PCR was performed to generate the construct of the NDUFV2
predicted promoter (a 461 bp genomic fragment of the 59-flanking
sequence upstream to its published translation initiation ATG),
using a set of specific primers for the human sequence, 59-
GCACACTGGATAGCAGCCCTCTG-39 and 59-GGCGGG
CCACACTGTTCACCTTC-39. The PCR blunted-end product
was subcloned into pSTBlue1 acceptor vector, using the Acceptor
Vector kit (Novagen, EMD Biosciences, US), digested with kPN1
and SacI and subcloned into kPN1/SacI sites of the reporter
vector pGL3 basic. Each of the constructs was analyzed by both
PCR and sequencing following digestion with the relevant
restriction enzymes.
Transient transfection and luciferase assay
Transient transfections of SH-SY5Y or SK-N-SH cells with 0.5–
2 mg plasmid DNA were carried out using FuGENE 6 (1:6 w:v)
(Roche Diagnostic Hoffmann-La Roche Ltd, Basel, Switzerland).
Luciferase assay was performed 12, 24 and 36 hrs after trans-
fection with optimal results at 24 hr after transfection, using
Luciferase assay kit (Promega Co. US). Luciferase activity was
measured by microplate luminometer (Anthos Lucy 1, Antos
Labtec Instruments, Salsburg, Austria). Cells transfected with the
insert or empty pGL3 basic served as a control. Transfected cells
were also incubated in the presence of 150 nM mithramycin, for
12, 24, 36 hrs, and subjected to the luciferase assay. To control for
mithramycin non-specific activity, cells were transfected with
pTAL-Luc and pAP1-Luc, which contains TATA-like promoter
and four tandem copies of the AP1, respectively.
Nuclear extract preparation and electrophoretic
mobility shift assay (EMSA)
Nuclear extracts were prepared from SH-SY5Y and SK-N-SH
cells as previously described [36]. For EMSA, three different
double stranded oligonucleotides, each containing a Sp1 consensus
binding site, were synthesized from the predicted promoter area of
the NDUFV2, and radiolabeled with [c
32P]-ATP, using poly-
nucleotide kinase. The forward oligonucleotides for NDUFV2 were
59-GGACTGGTCCCCGCCCCTCCCCCGGGAAG-39,5 9-GG
GAAGTCTCCCGCCCACAGGGCCCCAGC-39 and 59-CCG
TCAGCCCCCGCCCCTCGGCGAA GG-39. For EMSA, 3 mg
nuclear extract proteins were incubated with 0.5 ng of the
synthesized or 0.1 ng of the commercial (Promega Co. Madison
WI, US) [c
32P]-ATP end-labeled double strand oligonucleotide,
containing the consensus sequence for Sp1, for 20 min at room
temperature in binding buffer (10 mM Tris-HCl pH-8, 150 mM
Table 1. Demographic data for post mortem brains.
..................................................................................................................................................
Variable Control (n=15) Schizophrenia (n=15)
Age (years, means6SD) 48.1610.7 45.57612.95
Gender (male, female) 9M, 6F 8M, 6F
Postmortem interval (h, means6SD) 23.769.94 33.79615.16
Cause of death
Cardiac 13 6
Accident 22
Suicide 4
Other 3
Age of onset (years, means6SD) N/A 23.9367.72
pH (means6SD) 6.360.2 6.260.25
Brain hemisphere used (right:left) 8:7 9:5
Lifetime antipsychotic dose
a (mg, means6SD) 0 52428664401
Typical 5
Atypical 3
Both 3
None 3
History of psychosis 0 14
Current alcohol/drug abuse or dependence 0 3
Past alcohol/drug abuse or dependence 2 3
aLifetime antipsychotic dose in fluphenazine milligram equivalents. N/A–not applicable
doi:10.1371/journal.pone.0000817.t001
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0.2 mM DTT) in the presence of 1 mg poly-dIdC. In competition
experiments, a 100 fold molar excess of unlabeled double stranded
oligonucleotides or mithramycin 150 nM were added for 10 min
at room temperature before the addition of the
32P-labeled
oligonucleotides. For supershift analysis, 1 mg of Sp1specific
antibody (sc-59 X, Santa Cruz Biotechnology, Santa Cruz CA)
was preincubated with nuclear extract proteins for 1 hr at 4uC
before the addition of the DNA probes. DNA-protein complexes
were separated by electrophoresis in 5% polyacrylamide gel. Gels
were dried and visualized by autoradiography.
Statistical analysis
Results were analyzed for normal distribution using Kolmogorov-
Smirnov test. Normally distributed data were analyzed by one-way
ANOVA followed by post-hoc Dunnett test with comparison to
the control group. Data from postmortem brains that did not
distributed normally were analyzed by non-parametric Wilcoxon
Mann Whitney test. Differences in means between groups were
considered significant if p,0.05. For postmortem brain results,
age, gender, laterality, PMI, brain pH, duration of disease and
medication were added as covariates and the persistence of
a significant difference in main effect between diagnostic groups
was assessed by ANCOVA. Pearson’s correlation test was used for
the correlations between the expressions of all three genes, which
show normal distribution. SPSS version 14.0 software was used for
statistical analyses.
RESULTS
Sp1 expression is altered in schizophrenia and
parallels the region specific changes in complex I
subunits, NDUFV1 and NDUFV2
Previously, we have shown that in schizophrenia the mRNA and
protein expression of the NDUFV1 and NDUFV2 were increased in
platelets and lymphocytes [29] as well as in the ventral parieto-
occipital cortex, while reduced in the prefrontal cortex [13] as
compared with healthy subjects. In this study, we repeated these
findings using additional samples from the prefrontal and parieto-
occipital cortices, and expanded them by including specimens of
the striatum and lymphocytes. A significant reduction was
observed in mRNA levels of NDUFV1 and NDUFV2 in the
prefrontal cortex (67% p,0.001 and 48% p,0.0001 of control,
respectively) and the striatum (60%p,0.0001, 37% p,0.0001 of
control, respectively) (Fig 1A,B). In contrast, mRNA levels of
NDUFV1 and NDUFV2 were significantly increased in the ventral
parieto-occipital cortex (165%, p,0.03 and 208%, p,0.003 of
control, respectively) and in lymphocytes (242% and 342%,
p,0.0001 of control, respectively) (Fig 1C,D). Sp1 mRNA
expression was also altered in brain and in lymphocytes in
schizophrenia (Fig 1). Thus, Sp1 mRNA levels were significantly
decreased in the prefrontal cortex (66%, p,0.015) and in the
striatum (80%, p,0.038), while increased in the ventral parieto-
occipital cortex (158%, p,0.05 of control) and in lymphocytes
(480%, p,0.0001), showing region dependent changes parallel to
that of complex I subunits.
In order to further study the relationship between the two
subunits of complex I and Sp1, Pearson’scorrelation was performed
in all three brain regions the prefrontal cortex, the parieto-ocipital
and the striatum as well as in lymphocytes of normal subjects and
schizophrenic patients (Table 3). In normal subjects, Sp1 showed
a significant high correlation with both subunits of complex I in all
three brain regions and in lymphocytes, except for the NADUFV1 in
the parieto-ocipital. However, in patients, there was no significant
correlation between Sp1 and both genes in brain and lymphocytes,
except for NDUFV2 in the parieto-ocipital, and NDUFV1 in the
prefrontal cortex. Pooling all three-brain regions together demon-
strated a highly significant correlation between Sp1 and both genes
in normal subjects, while in schizophrenic patients there was no
correlation with NADUFV2, and Sp1 correlation with NADUFV1
was significantly reduced. Interestingly, the significant high
correlation that was observed between NDUFV1 and NDUFV2 in
normal subjects in all tissues examined, disappeared in schizo-
phrenic patients.
Table 2. Primer sequences and PCR conditions.
..................................................................................................................................................
mRNA primer sequence
Denaturing
temperature
and time uC (s)
Annealing
temperature
and time uC (s)
Elongation
temperature
and time uC (s)
Number of
cycles
Product size
(bp)
NDUFV2 S5 9-GGAGGAGCTTTATTTGTGCAC-39 94 (60) 55 (60) 72 (60) 35 640
NS 59-CCTGCTTGTACACCAAATCC-39
NDFUV1 S5 9-TACATCCGAGGGGAATTCTACA-39 94 (60) 60 (60) 72 (60) 35 426
NS 59-GTTCTTTCAAGGGCACAGACAT-39
NDUFS1 S5 9-TACTCGCTGCATCAGGTTTG-39 94 (60) 58 (60) 72 (60) 35 299
NS 59-CATGCATACGTGGCAAAATC-39
Sp1 S 59-GGAGAGCAAAACCAGCAGAC-39 95 (60) 60 (30) 72 (90) 35 335
NS 59-CAATGGGTGTGAGAGTGGTG-39
Reelin S 59-ATGTGGTAAAGGCGTTCCTG-39 95 (60) 58 (30) 72 (90) 35 382
NS 59-GGCCTTTTCAATGAAGACCA-39
b-actin S 59-TGAAGTGTGACGTGGACATCCG-39 94 (60) 60 (60) 72 (60) 25 447
NS 59-GCTGTCACCTTCACCGTTCCAG-39
18S-RNA S 59-AGGAATTGACGGAAGGGCAC-39 94 (60) 60 (60) 72 (60) 25 324
NS 59-GTGCAGCCC CGGACATCTAAG-39
All templates were initially denatured for 5 min at 94uC, and after completing all cycles, were extended a final extension of 10 min at 72uC.
doi:10.1371/journal.pone.0000817.t002
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side of brain, duration of disease and psychotropic medication
(lifetime antipsychotic dose expressed in fluphenazine milligram
equivalents) were added as covariates, and assessed by ANCOVA
for all three genes in all brain regions. Disease related significant
differences, and adjusted fold changes in mRNA after ANCOVA
analysis for all three genes in schizophrenia and controls are
presented in Table 4. None of the covariates could account for the
significant differences between groups. Following ANCOVA
analysis, the difference between groups remained significant for
all genes in all brain regions, except for Sp1in the striatum. In this
brain region none of the covariates had a significant effect on
group differences, except for PMI (p=0.012) which did not show
a significant correlation with Sp1 expression (r=0.257; p=0.17).
Mithramycin modulates mRNA expression of
NDUFV2, NDUFV1 NDUFS1 and RELN in SH-SY5Y
cells
In order to assess whether Sp1 is involved in the regulation of the
expression of complex I subunits, we treated SH-SY5Y cells with
mithramycin (150 nM). Mithramycin inhibited mRNA expression
of three subunits of mitochondrial complex I, NDUFV2, NDUFV1
and NDUFS1 as well as that of RELN in a time dependent manner
(Fig 2). Already after 12 hrs mithramycin administration induced
a marked reduction (73%, p,0.002) in mRNA levels of NDUFV2.
Following 24 hours of treatment a smaller but significant
reduction in the expression of NDUFS1 and RELN (30%,
p,0.007 and 44%, p,0.007, respectively), and a mild decrease
in mRNA levels of NDUFV1 (25% p,0.01) was also observed
(Fig 2B). No significant time dependent changes were observed in
Sp1 mRNA levels as well as in b-actin levels (Fig 2 C,D).
The inhibitory effect of mithramycin on protein levels of the
three subunits of complex I, the 24- 51- and 75-kDa encoded by
NDUFV2, NDUFV1 NDUFS1, respectively, was delayed and less
prominent compared to its effect on the transcription of these
genes. A mild, but significant, reduction of 23% p,0.005, 20%
p,0.01 and 10% p,0.02 in the 24- 51- and 75-kDa subunits,
respectively, was observed 24 hrs after administration of mithra-
mycin with no change in Sp1 protein levels (Fig 3). Similar results
were observed using the SK-N-SH human neuroblastoma cell line
(data not shown).
Figure 1. mRNA levels of NDUFV, NDUFV2 subunits of complex I and of Sp1 in post mortem brain specimens and lymphocytes of schizophrenic
patients and healthy controls. RNA was extracted from postmortem brain specimens of schizophrenic patients (SCH n=15) and healthy subjects
(Cont n=15), and from lymphocytes of 10 inpatients and 10 healthy subjects. A. Prefrontal cortex (BA 46/9), B. Striatum (including nucleus
accumbens), C. Ventral parieto-occipital cortex (BA19) and D. Densitometry values and a representative gel of mRNA levels in Lymphocytes.
doi:10.1371/journal.pone.0000817.g001
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PLoS ONE | www.plosone.org 6 September 2007 | Issue 9 | e817Table 4. The influence of covariates on disease related significant differences in mRNA of NDUFV1, NDUFV2 and Sp1in the
prefrontal and the parieto-occipital cortices and the striatum.
..................................................................................................................................................
Adjusted fold changes in mRNA
Schizophrenia/Normal
Significant group
difference (p)
Prefrontal Cortex NDUFV1 0.61 0.000
NDUFV2 0.67 0.029
Sp1 0.7 0.049
Striatum
NDUFV1 0.37 0.000
NDUFV2 0.43 0.000
Sp1 0.89 NS
Parieto-occipital cortex
NDUFV1 3.08 0.002
NDUFV2 1.72 0.050
Sp1 1.97 0.005
Data of ANCOVA analysis. Age, gender, PMI, brain pH, side of brain, duration of disease and psychotropic medication were included as covariates
doi:10.1371/journal.pone.0000817.t004
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Figure 2. Inhibition of the transcription of NDUFV1, NDUFV2 and NDUFS1 subunits of complex I and of Sp1 and RELN by mithramycin in human
neuroblastoma SH-SY5Y cells. Cell were treated for 12, 24 and 36 hrs with 150 nM mithramycin and mRNA levels of all 5 genes were analyzed by RT-
PCR. A. NDUFV2. B. NDUFV1 and NDUFS1 and RELN after 24 hrs treatment with mithramycin. C. Sp1 and D. A representative gel, demonstrating
mithramycin inhibition of the expression of the three subunits of complex I and of RELN with no change in Sp1 and b-actin. Results are means6SD of
3–4 experiments.
doi:10.1371/journal.pone.0000817.g002
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region and its modulation by Sp1
In our previous studies, out of the three complex I subunits,
NDUFV2 showed the greatest abnormality in schizophrenic
patients [13,29]. In addition, the present study demonstrate that
NDUFV2 transcription was strongly affected by mithramycin in
SH-SY5Y and SK-N-SH cells, suggesting an important regulatory
role for Sp1 transcription factors in its expression. Therefore, we
used this gene to further study the role of Sp1 in its transcription.
First, we tested whether the 461 bp genomic fragment of the 59-
flanking sequence upstream to NDUFV2 published translation
initiation ATG has promoter activity by subcloning into
a luciferase reporter plasmid and transfecting SH-SY5Y or SK-
N-SH cells. As predicted, cells transfected with the construct
containing the 461 bp genomic fragment of NDUFV2 demon-
strated a dose dependent increase in luciferase activity as
compared to control cells transfected with pGL3 basic or
untransfected cells (Fig 4A), indicating its promoter activity.
Administration of 150 nM mithramycin 1 hr before the trans-
fection significantly reduced the promoter activity, expressed as
60–65% reduction in luciferase activity (Fig 4B). Mithramycin,
induced a 10–15% reduction in luciferase activity in cells
transfected with pTAL-Luc and pAP1-Luc, which do not contain
GC-rich enhancer. The latter may be due to a reduction in overall
activity of cells in the presence of mithramycin. Alternatively, this
reduction may result from the inhibition of Sp1-dependent
transcription of genes encoding proteins that activate AP1 and
TATA. Nevertheless, the four-fold inhibition of luciferase activity
in cells transfected with the NDUFV2 promoter fragment, points to
the involvement of Sp1 in the regulation its activity.
Sp1 binds to the promoter region of NDUFV2
GC-rich promoter elements are able to interact with a number of
zinc finger transcription factors, including members of the Sp1
family and Kruppel-like factors [37,38]. Moreover, mithramycin,
which binds to GC-rich sites on DNA, is not a specific inhibitor of
Sp1. Therefore, to test whether it is Sp1 that interacts with
NDUFV2, we studied Sp1 binding to its 461 bp promoter region in
the presence and absence of Sp1 specific antibody. Three putative
Sp1 elements were synthesized as probes including the 2120 to
2147 region (I), the 2171 to 2200 region (II) and the 2194 to
2223 region (III). Gel mobility shift assay (Fig 5) revealed that all
three probes formed DNA-protein complexes when incubated
with SH-SY5Y nuclear extract (lane 2 for oligo 1–3) similar to that
formed by double strand commercial probe containing the
consensus sequence for Sp1 (lane 2 for Sp1 consensus). Addition
of a 100 fold molar excess of the matching unlabeled double
stranded probe (lanes marked 3), as well as 150 nM mithramycin
(lanes marked 5) inhibited the formation of the DNA-protein
complexes. Addition of Sp1 antibody to the binding reaction
induced a supershifted band in all three probes, similar to their
effect on the commercial Sp1 probe (lanes marked 4). These results
further confirm the involvement of Sp1 in the regulation of
NDUFV2 promoter. The free, synthesized and commercial, [c
32P]-
ATP end-labeled double stranded probes, are depicted in lanes
marked 1.
DISCUSSION
Previously, we have reported schizophrenia and tissue specific
alterations in the expression of complex I subunits, NDUFV1 and
NDUFV2, both at the level of mRNA and protein [13,29]. This,
Figure 3. Protein levels of NDUFV1, NDUFV2 and NDUFS1 subunits of
complex I, but not that of Sp1 are reduced following treatment of
SH-SY5Y cells with mithramycin. Densitometry value of protein levels
(A) and a representative gel (B) of all 4 genes in cells treated for 24 hrs
with 150 nM mithramycin. Results are means6SD of 3–4 experiments.
*p,0.005 **p,0.014 ***p,0.024 vs. untreated control cells.
doi:10.1371/journal.pone.0000817.g003
Figure 4. The effect of mithramycin on the transcriptional activity of
the NDUFV2 predicted promoter in SH-SY5Y cells. A. Cells were
transiently transfected with two concentrations of the pNDUFV2-Luc
reporter construct (construct) for 24 hrs and analyzed for luciferase
activity. B. One hour before the transfection cells were pre-incubated
with or without mithramycin (150 nM). The results are means6SD of
three experiments normalized for10
6 cells. *p,0.0001.
doi:10.1371/journal.pone.0000817.g004
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expression of different groups of genes in schizophrenia [9,39],
may point to abnormal transcriptional regulation in the disorder.
Indeed, in the present study we show that the expression of the
ubiquitously expressed transcription factor Sp1 is altered in
schizophrenia, in brain and in lymphocytes, as compared with
normal controls. Specifically, Sp1 mRNA expression was down-
regulated in the prefrontal cortex and the striatum, while up-
regulated in the parieto-occipital cortex and in lymphocytes of
schizophrenic patients. This opposite alteration in Sp1 expression
in different brain regions is not unique for schizophrenia. Indeed,
in Huntington’s Disease (HD) it was previously reported that Sp1
levels were robustly increased in caudate postmortem tissues but
decreased in the hippocampus [40].
The changes observed in Sp1 expression in schizophrenic
subjects parallel the tissue specific pattern of alteration in NDUFV1
and NDUFV2 mRNA levels. In addition, a significant high
correlation was observed between Sp1 and both NDUFV1 and
NDUFV2 in normal subjects in all three brain regions. However, in
schizophrenic patients the correlation between Sp1 and both
NDUFV2 and NDUFV1 was distorted. In concordance with brain
findings, a highly significant correlation between Sp1 and both
subunits of complex I was observed in lymphocytes of normal
subjects, which was eradicated in schizophrenic patients. Similarly,
no correlation was observed between NDUFV2 and NDUFV1 in
schizophrenic patients in all tissues examined. In normal subjects,
however, a significantly high correlation was observed, as expected
from the reported stoichiometry of 1 mol of each subunit for 1 mol
of complex I [41]. These results suggest that Sp1 is involved in the
regulation of the expression of both subunits of complex I.
It has been previously reported that Sp1 can be regulated at the
level of transcription [14]. However, in order to find out whether
the changes in mRNA levels are also expressed at the protein level,
the active form of Sp1, we have analyzed Sp1 protein levels in
brain specimens of schizophrenic patients and healthy subjects.
Unfortunately, we ran out of protein samples from the prefrontal
and the pariet-ocipital cortices, therefore we measured Sp1 in the
striatum and the cerebellum. Protein levels of Sp1 in the striatum
were significantly decreased by 42% in schizophrenic patients as
compared to healthy subjects (2.3960.31 vs. 1.3860.27,
p,0.0001, expressed as normalized OD values). Interestingly, in
the cerebellum, where there was no significant difference in
mRNA levels of both NDUFV1 and NDUFV2 between the
schizophrenic and the normal groups, no significant change was
observed in protein and mRNA levels of Sp1. Taken together, the
results of this study in human subjects suggest that a defect in Sp1
transcriptional activity may play an important role in the
abnormal expression of complex I subunits in schizophrenia.
One may argue that the alterations in the expression of complex
I subunits and Sp1 may be due to the effect of antipsychotic
medication. Indeed, it has been reported that chronic treatment
with antipsychotic drugs affects the expression of many genes
Figure 5. Sp1 binding to its three consensuses sequences in the 461 bp promoter sequence of NDUFV2. For electrophoretic mobility shift assay
nuclear extracts of SH-SY5Y cells were incubated with the three double strand
32P-end labeled oligonucleotides (specified in Material and Method
section), and a commercial
32P-end labeled oligonucleotides containing the consensus sequence for Sp1 (Sp1 consensus) in the presence (lanes
marked 3) or absence (lanes marked 2) of cold competitors, or 150 nM mithramycine (lanes marked 5). For supershift assay, nuclear extracts were
preincubated with Sp1 antibody prior to the addition of the appropriate oligonucleotide (lanes marked 4). Lanes marked 1 are free end-labeled
probes.
doi:10.1371/journal.pone.0000817.g005
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and genes involved in lipid biosynthesis [42–45]. However, in the
present study medication, taken as a covariate, did not affect the
significance of differences observed between the patients and the
healthy subjects, in mRNA levels of both subunits of complex I
and of Sp1, in all brain regions and in lymphocytes. Moreover, in
our previous studies antipsychotic medication had no effect on the
alterations in mRNA and protein levels of complex I subunits in
postmortem brain specimens of antipsychotic treated schizophren-
ic as well as bipolar patients [13,29]. Another confounding factor
in postmortem brain studies, which has been extensively
addressed, is the pH of the samples [46–48]. Although the
mechanism by which pH affects the expression of genes is still
unclear, it has been reported that the pattern of gene expression
differs between low and high pH-brain specimens [46,47].
However, in our study adding pH as a covariate did not change
the disease related effects on the complex I subunits and on Sp1,
similar to its lack of effect on the disease related differences in
other genes such as glucocorticoid receptor, phosphorylated and
non-phosphorylated cytosolic protein kinase Ce and kainate
receptor 2 [49]. We therefore assume that disrupted Sp1
transcriptional activity is associated with schizophrenia pathology
rather than its treatment.
Further evidence supporting the involvement of Sp1 in the
transcription of the schizophrenia relevant genes, is the ability of
mithramycin, which inhibits Sp1 binding to DNA GC-rich sites, to
inhibit the expression of those genes. Mithramycin induced a time
dependent decrease in mRNA and protein levels of complex I
subunits NDUFV1, NDUFV2 and NDUFS1, as well as of reelin,
which was arbitrarily chosen as a gene known to be modulated by
Sp1 and repeatedly reported to be abnormally expressed in
schizophrenia [19,50]. In our previous studies, the expression of
NDUFS1 was not significantly altered in schizophrenia in the
prefrontal and the parieto-occipital cortices and in lymphocytes.
However, in the cerebellum there was a significant reduction in
NDUFS1 (unpublished data). Moreover, it was reported that in
a subgroup of early onset schizophrenic patients, NDUFS1 was
abnormally expressed in their lymphocytes [51]. These findings
can be related to Sp1 being differentially subjected to endogenous
or exogenous environmental stimuli [14–17], and possibly to the
involvement of additional transcription factors in the expression of
NDUFS1 in vivo.
In order to further study whether Sp1 plays a role in the
regulation of genes abnormally expressed in schizophrenia, we
chose the NDUFV2 subunit of complex I, which was the most
substantially affected in schizophrenia in both brain and
periphery. First, we identified a promoter-like activity in the
461 bp genomic fragment of the 59-flanking sequence upstream to
the translation initiation ATG. The involvement of Sp1 in the
activation of this promoter sequence, which contains three GC-
rich elements, was then demonstrated by the robust reduction in
its promoter activity in the presence of mithramycin.
GC-rich promoter sequences are able to interact with a number
of zinc-finger transcription factors, including other members of
Sp, Kruppl like factors, and TGF-b-inducible early gene families
[18,37,38,52]. Therefore, reduced expression as well as reduced
promoter activity following mitramycin treatment may be due to
other zinc-finger transcription factors. Therefore, competition gel
shift assays were performed. GC-boxes are the only putative
binding site in the NDUFV2 TATA-less promoter sequence.
Competition gel shift assays in the presence and absence of
mithramycin, as well as supershift assays, have confirmed that Sp1
is one of the nuclear factors involved in the regulation of NDUFV2
promoter. However, it is possible that other members of the zinc-
finger transcription factors and of the Sp family will compete for
binding of the three GC-rich sequence of the NDUFV2 promoter,
specifically Sp3 and Sp4, which share great homology with Sp1
and are able to recognize GC-box with identical affinities [14].
Further studies are needed to determine whether these zinc-finger
transcription factors, in general, and the other Sp family
members, in particular, are of relevance to the abnormalities
observed in the other subunits of complex I implicated in
schizophrenia.
Sp1 is a ubiquitously expressed transcription factor and is
essential for the basal transcription of many genes containing the
Sp1 binding site(s). However, evidence has accumulated support-
ing the specificity of Sp1 regulation. Alterations in its abundance
were observed under various conditions such as during de-
velopment, increased calcium, viral infection and hypoxia
[14,16,53]. In addition, many studies have shown that Sp1 can
play a role in the regulation of certain genes in response to specific
signals. Thus, Sp1 activity can be regulated by diverse factors
including high glucose and glucosamine, growth factors such as
TGF-b and intracellular signaling such as cAMP, PKC and ERK,
as well as by interaction with other nuclear factors [14–
17,52,54,55]. A study investigating the effect of such factors on
Sp1 transcriptional activity and on the expression of complex I
subunits as well as on other genes implicated in schizophrenia, is
underway. In conclusion, the results of the present study,
demonstrating disrupted expression of Sp1 associated with parallel
impairments in complex I subunits, for which Sp1 is probably
a transcription factor, suggest a key role for Sp1 in the
pathogenesis of schizophrenia. The involvement of Sp1 in the
regulation of many genes currently implicated in schizophrenia,
together with the duality of Sp1 having a ubiquitous as well as
environmental and intracellular specific signal regulated transcrip-
tional activities, concur with the multi gene abnormality and
symptom heterogeneity observed in schizophrenia.
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